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Abstract 
Background: Diabetic retinopathy is the main cause of preventable blindness in the economically active popula-
tion in western countries. Diabetic retinopathy screening is effective in preventing blindness and can be performed 
through various diagnostic methods. Our objective is to compare binocular indirect ophthalmoscopy (BIO) to 
telemedicine protocols of digital retinography for diabetic retinopathy screening in a large and heterogenous type 1 
diabetes population in a developing country.
Methods: Data from 1266 Type 1 Diabetes Mellitus patients from a Brazilian multicenter study were analyzed. 
Patients underwent BIO and digital retinography, non-mydriatic and mydriatic. Images were sent to a reading center 
in a telemedicine protocol. Agreement between the different methods was calculated with kappa statistic for diabetic 
retinopathy and maculopathy classification. Clinical outcome was either observation or referral to specialist.
Results: Agreement between BIO and mydriatic retinography was substantial (kappa 0.67–0.74) for diabetic retin-
opathy observation vs referral classification. Agreement was fair to moderate (kappa 0.24–0.45) between retinography 
and BIO for maculopathy. Poor mydriasis was the main obstacle to image reading and classification, especially on the 
non-mydriatic strategy, occurring in 11.9 % of right eyes and 16.9 % of left eyes.
Conclusion: Mydriatic retinography showed a substantial agreement to BIO for diabetic retinopathy observation vs 
referral classification. A significant amount of information was lost on the non-mydriatic technique because of poor 
mydriasis. We recommend a telemedicine-based diabetic retinopathy screening strategy with digital mydriatic reti-
nography, preferably with 2 fields, and advise against non-mydriatic retinography in developing countries.
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Background
Diabetic retinopathy (DR) is one of the main causes of 
preventable blindness in the world, affecting 12.6 million 
and threatening the vision of 37.3 million in 2010 [1]. It is 
the main cause of preventable blindness in the economi-
cally active population in developed countries [2]. Dia-
betes mellitus (DM) accounts for more than 10 % of the 
health care budget of some countries, with DR being one 
of the main expenditures related to DM.
DR screening has been considered to have an excellent 
cost-effectiveness [3, 4], allowing the detection of early 
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stages of the disease, preventing visual impairment and 
decreasing the economic burden of DR treatment [5–9].
DR may impair vision in its advanced stages and also 
because of diabetic macular edema, which may occur at 
any stage of this diabetic chronic complication. DR can be 
diagnosed by binocular indirect ophthalmoscopy (BIO), 
with or without slit-lamp biomicroscopy, or through reti-
nal photographs (retinographies) [10]. The Early Treat-
ment Diabetic Retinopathy Study (ETDRS) established a 
gold standard of 7-field stereoscopic photographs for the 
diagnosis of DR [11].
Brazil, a country of continental dimensions, has 
approximately 12 million people between 20 and 79 years 
old with diabetes [12]. There are currently no nation-
wide studies of DR prevalence in Brazil, but available 
data point to a prevalence ranging from 7.62 to 44.4 % of 
patients with diabetes, representing 0.9–5.3 million peo-
ple [13–19].
Brazil, along with several other developing countries, 
does not have a national screening DR program, except 
regional initiatives of detection of cases that mainly rely 
on BIO [13–19].
Telemedicine has been established as a successful strat-
egy for DR screening in various countries [6–8]. Digital 
retinographies can be obtained by non-medical trained 
personnel and sent to reading centers, where specialists 
are able to classify DR and categorize patients in terms of 
observation or referral.
The aim of this study was to compare binocular indi-
rect ophthalmoscopy (BIO) and digital retinography 
(mydriatic and non-mydriatic) for the screening of DR in 
a large multicenter type 1 DM patients study.
Methods
Patients
This multicenter study included type 1 DM patients 
from 7 referral centers located in 4 different Brazilian 
regions (South, Southeast, Northeast and Center-West). 
Inclusion criterion was type 1 DM according to the 
American Diabetes Association [20] and exclusion cri-
teria were any other eye diseases that produced retinal 
changes. Written informed consent was obtained from 
all patients, and the local ethics committee approved the 
study protocol.
Methods
Each patient had both eyes examined, whenever possi-
ble, and underwent non-mydriatic retinography (NMR), 
mydriatic 2 field retinography (one field centered on the 
fovea and the other field centered on the optic disc) and 
mydriatic BIO.
At the reading center, mydriatic retinography centered 
on the fovea alone was considered as 1-field retinography 
(1FR) and combined mydriatic retinographies were con-
sidered as 2-field retinography (2FR).
Mydriasis was obtained with 1  % tropicamide drops. 
BIO was performed with an Eyetec Ophthalmoscope 
(Eyetec, São Carlos-SP, Brazil) and a 20 diopter lens (Volk 
Optical, Mentor, OH, USA) by an experienced retinal 
specialist in each center. After BIO, each eye was classi-
fied for diabetic retinopathy and maculopathy according 
to the American Academy of Ophthalmology guidelines 
[10] (Tables 1, 2).
Clinical outcome was either observation or referral to 
the ophthalmologist. For the present study, the follow-
ing criteria were adopted for referral: moderate or severe 
non-proliferative diabetic retinopathy, proliferative dia-
betic retinopathy, or apparently present diabetic macular 
edema [21, 22].
For some sub-analysis, eyes were separated in two 
groups: the least severe group (absent or mild to moder-
ate non-proliferative diabetic retinopathy) and the most 
severe group (severe non-proliferative or proliferative 
diabetic retinopathy).
Retinographies were performed with a Canon CR-s 
Digital Retinal Camera (Canon Inc, Melville, NY, USA); 
images were obtained at 45° angles and 3168 × 4752 pix-
els resolution. Retinographies were taken by previously 
trained non-medical personnel and sent in the DICON 
(Digital Imaging and Communications in Medicine) 
protocol to the reading center (MediViewWeb software, 
version 4.0.75, Medilab, Rio de Janeiro, Brazil). All reti-
nographies in each center were taken by the same trained 
individual.
Readings were performed by retinal specialists and 
began with the evaluation of the quality of images, 
regarding transparency of the media, focus and image 
boundaries. Third order retinal vessels needed to be 
identified. Images needed to display (Fig. 1):
  • For fovea-centered retinographies: both temporal 
vascular arcades and at least half disc diameter of 
retina nasal to the optic disc;
  • For optic disc-centered retinographies: the four vas-
cular arcades and at least one disc diameter of retina 
temporal to the fovea.
The reading sequence of retinographies was as follows: 
first, NMR of each eye followed by 1FR and finally 2FR. 
Reading was performed with a 19″ monitor, and zoom was 
used according to the readers’ convenience. Reading was 
performed in an independent and masked fashion, and no 
additional clinical information was given to the readers.
The classification system for retinographies was 
adapted from the Scottish Diabetic Retinopathy screen-
ing program [22] (Tables 1, 2).
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To allow comparison of a clinical diagnostic method 
(BIO) with digital retinographies, we proposed an equiv-
alence classification system (Tables 1, 2).
Finally, for patients analyses instead of eyes analyses, 
we considered the eye with the most severe classification, 
and 2FR, preferably. All eyes with evidence of laser treat-
ment were considered “proliferative diabetic retinopathy”.
The A1C was measured by HPLC (TOSOH G7, Lux-
embourg, Belgium) (nv: 4.0–5.6 %).
Statistics
All data were collected in MS Excel 2010 files (Microsoft 
Corporation, Redmond, WA, USA). Statistical analyses 
were performed with “R” software, version 3.1.1 (R Foun-
dation for Statistical Computing, Vienna, Austria) and 
SPSS 19.0 for Windows (SPSS Inc., Chicago, IL, USA).
For agreement analyses, we used Kappa statistics [23], 
with the following ranges of agreement: 0 to 0.19—poor 
agreement; 0.2 to 0.39—fair agreement; 0.4 to 0.59—
moderate agreement; 0.6 to 0.79—substantial agreement 
and 0.8 to 1.00—almost perfect agreement [24]. Exact 
Fischer or Chi square tests were used for unpaired varia-
bles, and the McNemar test was used for paired variables. 
The 5  % level of significance was used. Binomial distri-
bution was used for confidence interval for proportions 
calculation. The Mann–Whitney test was used to assess 
group differences for quantitative variables [25–27].
Results
The number of participants who underwent at least two 
methods was 1266, with 56.8 % women. Comparison of 
the clinical outcome (observation or referral) between 
the group of patients who underwent all methods and the 
group of patients that missed at least one method showed 
homogeneity (p  =  0.2471). The number of patients 
that underwent each method is displayed in Fig.  2. The 
Table 2 Diabetic maculopathy classification
a Only in cases of absent or mild non-proliferative diabetic retinopathy: in more severe stages of DR, the outcome is referral
Severity level Ophthalmoscopy changes Retinography changes Outcome
Apparently absent diabetic macular edema Absence of retinal thickening or hard exu-
dates on the posterior pole
No alterations Observationa
Apparently present diabetic macular edema Retinal thickening or hard exudates on the 
posterior pole
Lesions within 2 disc diameters from the 
foveal center; any hard exudate
Referral
Fig. 1 Retinography areas. 1 For fovea-centered retinographies, images should display both temporal vascular arcades and at least half disc diam-
eter of retina nasal to the optic disc. 2 For optic disc-centered retinographies, images should display the four vascular arcades and at least one disc 
diameter of retina temporal to the fovea
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number of participants who had both eyes evaluated by 
the four methods (BIO, NMR, 1FR, 2FR) was 1023.
The following data are given as mean (standard devia-
tion) and median (range). Age (years), diabetes duration 
(years) and hemoglobin A1C (percentage) were respec-
tively: 31 (12) and 29 (8–73); 16 (9) and 15 (0–56); and 
10.6 (2.8) and 10.4 (5.0–18.6).
Quality was considered adequate in over 93, 74, 91 and 
91  % of eyes for BIO, NMR, 1FR and 2FR, respectively. 
The main causes for poor quality are shown in Fig. 3.
DR and maculopathy classification in each center, in 
the four different Brazilian regions, is shown in Table 3. 
Classifications are based on the most severely affected 
eye and 2FR strategy, preferably.
Considering DR and maculopathy classification in the 
worst eye, 69  % of patients were “observable” and 31  % 
“referable” (see “Methods”).
When BIO and mydriatic retinography screening meth-
ods were compared regarding DR classification for the 
main outcome (observation versus referral), agreement 
Total patients 
enrolled = 1266
Patients who 
underwent 
BIO = 1206
Patients who 
underwent 
NMR = 1099
Patients who 
underwent 
1FR = 1100
Patients who 
underwent 2FR= 
1094
Fig. 2 Number of patients in each diagnostic method. BIO binocular indirect ophthalmoscopy, NMR non-mydriatic retinography, 1 FR 1 field mydri-
atic retinography, 2 FR 2 field mydriatic retinography
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
14.00%
16.00%
18.00%
POOR MYDRIASIS
CATARACT
OTHER
Fig. 3 Causes for poor quality of images. BIO binocular indirect ophthalmoscopy, NMR non-mydriatic retinography, 1 FR 1 field mydriatic retinogra-
phy, 2 FR 2 field mydriatic retinography, RE right eye, LE left eye
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was substantial (kappa 0.67–0.74). However, when BIO 
and non-mydriatic screening methods were compared 
regarding DR classification for the same outcome, agree-
ment was only moderate (kappa 0.58). When BIO and the 
retinographies strategies were compared regarding mac-
ulopathy classification, agreement was fair to moderate 
(kappa 0.24–0.45). Agreement analysis is shown in Fig. 4.
Poor mydriasis was the main cause of poor quality in 
NMR, occurring in 11.92 % of right eyes and 16.96 % of 
left eyes. Poor mydriasis accounted for less than 1  % of 
poor quality in the mydriatic methods.
Poor mydriasis did not allow classification in 8.5 % of 
right eyes that underwent NMR, ranging 3.1–10.6  % in 
the various centers, and 12.1 % of left eyes, ranging 7.1–
20 % in the various centers.
Poor mydriasis usually led readers to overestimate the 
DR stage in NMR, when compared to the classification 
for the same eyes with mydriatic methods. About 70  % 
of eyes with poor mydriasis in NMR that received a dif-
ferent classification in 1FR or 2FR were considered more 
severely affected in NMR (67.9 and 73.3 % of right eyes 
and 68.3 and 78.7 % of left eyes with 1FR for retinopathy 
and maculopathy, respectively; 67.7 and 73.1  % of right 
eyes and 68.1 and 78.0 % of left eyes with 2FR for retin-
opathy and maculopathy, respectively).
Patient age and retinopathy severity were associated 
with poor mydriasis or impossibility of classification in 
NMR. The average age of the patients with good mydri-
asis in NMR was 28 years old, whereas 36 years old for 
patients with poor mydriasis in NMR (p  <  0.0001). The 
worse the severity of diabetic retinopathy, according to 
2FR classification, the higher the percentage of eyes with 
poor mydriasis in NMR. For this sub-analysis, eyes were 
separated into two groups: the least severely affected and 
the most severely affected (see “Methods”). Eyes with 
poor mydriasis in NMR in the “least severe” group were 
12  % right eyes and 15.1  % left eyes, whereas eyes with 
poor mydriasis in NMR in the “most severe” group were 
62  % right eyes and 56  % left eyes. All differences were 
statistically significant (p < 0.0001).
BIO allowed for the classification of most eyes (58.1 %) 
that could not be properly classified by 2FR strategy.
Discussion
We found a substantial agreement (kappa 0.67–0.74) 
between BIO and mydriatic retinographies for diabetic 
retinopathy classification regarding clinical outcome 
(observation vs referral), but only moderate agreement 
(kappa 0.58) between BIO and non-mydriatic retinography. 
The main factor that prevented diabetic retinopathy classi-
fication in the present study was poor mydriasis in NMR.
Our results agree with previous reports [28–30] that 
also observed problems with NMR. Left eyes were most 
affected by poor mydriasis (Fig.  3): after the first reti-
nography taken on the right eye, both pupils contract 
because of the flash, making it more difficult to obtain 
enough mydriasis on the second (left) eye. Poor mydriasis 
in NMR promoted classification errors, because of shad-
ows or reflexes on the image, usually leading the reader 
to overestimate the severity in about 70 % of eyes. Poor 
mydriasis was observed more often in older patients or in 
eyes with more severe stages of retinopathy. Poor mydri-
asis was the only modifiable factor that prevented a read-
able image, since it dropped considerably in the mydriatic 
methods, whereas all other factors persisted (Fig. 3). Our 
findings advise against a diabetic retinopathy screening 
strategy with conventional non-mydriatic retinography. 
Ultra-wide field retinography is not currently a possible 
screening strategy in developing countries because of 
high costs [31–33].
Table 3 Diabetic retinopathy and  maculopathy classification in  each center, in  four different Brazilian regions (South-
east, South, Northeast and Center-West)
DR diabetic retinopathy, NP non-proliferative, MAC maculopathy, BIO binocular indirect ophthalmoscopy
Center 1
Southeast
Center 2
Southeast
Center 3
Southeast
Center 4
Southeast
Center 5
South
Center 6
Northeast
Center 7
Center-West
Total
DR-absent 109 (60.6 %) 118 (45.9 %) 71 (41.0 %) 31 (32.6 %) 89 (49.4 %) 82 (50.3 %) 108 (49.5 %) 608 (48.0 %)
DR-NP mild 35 (19.4 %) 91 (35.4 %) 53 (30.6 %) 33 (34.7 %) 44 (24.4 %) 42 (25.8 %) 54 (24.8 %) 352 (27.8 %)
DR-NP moderate 10 (5.6 %) 12 (4.7 %) 5 (2.9 %) 6 (6.3 %) 8 (4.4 %) 4 (2.5 %) 7 (3.2 %) 52 (4.1 %)
DR-NP severe 8 (4.4 %) 9 (3.5 %) 4 (2.3 %) 0 (0.0 %) 3 (1.7 %) 4 (2.5 %) 6 (2.8 %) 34 (2.7 %)
DR-proliferative 14 (7.8 %) 20 (7.8 %) 29 (16.8 %) 18 (19.0 %) 27 (15.0 %) 22 (13.5 %) 29 (13.3 %) 159 (12.6 %)
DR-impossible 4 (2.2 %) 7 (2.7 %) 11 (6.4 %) 7 (7.4 %) 9 (5.0 %) 9 (5.5 %) 14 (6.4 %) 61 (4.8 %)
Total retinopathy 180 (100 %) 257 (100 %) 173 (100 %) 95 (100 %) 180 (100 %) 163 (100 %) 218 (100 %) 1266 (100 %)
MAC-apparently absent 141 (78.3 %) 201 (78.2 %) 137 (79.2 %) 72 (75.8 %) 144 (80.0 %) 124 (76.1 %) 161 (73.9 %) 980 (77.4 %)
MAC-apparenlty present 32 (17.8 %) 42 (16.4 %) 14 (8.1 %) 13 (13.7 %) 18 (10.0 %) 25 (15.3 %) 35 (16.1 %) 179 (14.1 %)
MAC-impossible 7 (3.9 %) 14 (5.4 %) 22 (12.7 %) 10 (10.5 %) 18 (10.0 %) 14 (8.6 %) 22 (10.1 %) 107 (8.5 %)
Total maculopathy 180 (100 %) 257 (100 %) 173 (100 %) 95 (100 %) 180 (100 %) 163 (100 %) 218 (100 %) 1266 (100 %)
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Mydriatic 1-field and 2-field retinography strategies had 
an almost perfect agreement (kappa 0.91–0.93). How-
ever, a small percentage (5.08  %) of observable patients 
according to 1FR were considered referable according 
to 2FR. These patients probably had significant changes 
in the nasal retina. As it is extremely easy and not time-
consuming to obtain the second photo once the pupils 
are dilated, we believe that our findings support a 2-field 
protocol screening strategy [29].
Our results showed that BIO agreed substantially with 
digital retinography only regarding the clinical outcome 
(observation or referral), but they did not show a good 
agreement in DR classification if all stages were consid-
ered. BIO and retinographies did not show a good agree-
ment regarding diabetic maculopathy (Fig. 4), either. BIO 
usually does not allow for identification of minor changes 
such as microaneurysms, retinal neovessels or mild mac-
ular edema [34], and probably that was the reason why 
BIO did not show a good agreement with retinographies 
regarding retinopathy and maculopathy classification. 
According to BIO, only 4  % of eyes had maculopathy, 
whereas maculopathy was present in 9 % of eyes accord-
ing to 2FR. Additionally, BIO can only be performed by a 
specialist, precluding a telemedicine-based strategy.
The ETDRS protocol is still the gold standard for dia-
betic retinopathy classification, but it is very time-con-
suming and requires a highly trained professional for 
image acquisition [35]. Protocols with a smaller number 
of fields [6, 36, 37], as well as protocols with digital reti-
nographies [38, 39], have already been validated for DR 
screening. In the present study, we used a 2-field digital 
retinography protocol that required less than 5 min per 
patient.
Besides poor mydriasis, some documentation for the 
present study was lacking because of improper tech-
nique. We believe this problem may be resolved with 
better training of the personnel, since there is a learning 
curve for retinography acquisition [40]. Some anatomi-
cal features of the eye may also render the examination or 
the reading especially difficult, for example, high myopic 
eyes with a hypopigmented fundus [41].
The referral criteria for the present study encompassed 
patients with moderate non-proliferative diabetic retin-
opathy or worse [21]. Patients with moderate non-prolif-
erative retinopathy are clinically followed and not treated, 
and the inclusion of this stage might have overestimated 
the referral burden. However, our study still concluded 
that such classification would decrease the referral bur-
den by about 70 %.
ETDRS classified diabetic macular edema into clini-
cally significant (treatable) and non-clinically significant 
(observable). Our study evaluated only indirect signs of 
macular edema, such as hard exudates, but not retinal 
thickening itself. Hence, instead of using ETDRS clas-
sification, we employed the classification “apparently 
present” or “apparently absent” [10], with the former 
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corresponding to both “observable maculopathy” and 
“referable maculopathy” categories from the Scottish 
grading system [10]. All patients with an “apparently pre-
sent” macular edema were considered referable in the 
present study.
The global increase in the prevalence of diabetes mel-
litus calls for the optimization of human and economic 
resources. One of the main advantages of telemedicine is 
that it allows for a decreased proportion of patients that 
otherwise would have been referred to a specialist [5, 
7–9, 42]. Our results showed that around 70 % of exam-
ined patients would be observable, thereby alleviating the 
demand for the specialist.
BIO and retinography are both valid strategies for DR 
screening. The main advantages of BIO are its ease of 
handling and low cost [13]. BIO may perform superiorly 
in certain circumstances in comparison to retinogra-
phies, as in cases of media opacities or poor patient col-
laboration, for example. In our study, BIO allowed for the 
classification of most eyes that could not have been prop-
erly classified by 2FR strategy. BIO has some disadvan-
tages, such as not being sensitive enough to detect minor 
signs of DR [34]. The main disadvantages of the retinog-
raphy strategy are its cost and its poor performance in 
unfavorable anatomical features, as stated above. How-
ever, the central issue regarding the comparison of BIO 
and retinographies is that the former depends on the 
presence of a specialist, whereas the latter is compat-
ible with telemedicine strategies. The current and future 
demands for retinal evaluation due to the global diabetes 
epidemics is not compatible with the presence of a spe-
cialist for every fundus exam [43]; telemedicine also is a 
feasible screening strategy for remote locations or areas 
with an uneven distribution of specialists.
This is the first Brazilian multicenter study that com-
pared several DR screening methods in type 1 DM 
patients; we believe that our results could be extrapolated 
to other developing countries with remote areas and an 
uneven distribution of specialists.
This study had limitations. First, it was not designed 
to compare DR strategies to the gold-standard, ETDRS 
7-field protocol. However, the ETDRS protocol is not 
suitable as a screening technique since it requires expert 
photographers and is time-consuming [44]. Addition-
ally, the present study included only patients enrolled in 
referral urban centers. Further studies should also enroll 
patients from other settings, such as rural areas or pri-
mary care units. Future research on telemedicine and DR 
screening should also evaluate the practical impact of 
such measures in the decline of diabetic retinopathy as a 
major cause of blindness, as was the case in England and 
Wales [44]. Automatic detection of DR combined with 
telemedicine is also a promising field of research [44], as 
well as the study of other layers of interventions, such as 
telemedicine with health education and promotion, in 
order to improve DR screening coverage [45].
Conclusions
Our study showed that BIO and a telemedicine-based 
mydriatic retinography protocol are equivalent methods 
for DR screening. Because of its cost-effectiveness and its 
role in regions where specialists are unavailable, we rec-
ommend the telemedicine-based mydriatic strategy for 
DR screening.
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